Relmada Therapeutics (RLMD) Return on Capital Employed (2013 - 2026)

Relmada Therapeutics (RLMD) has 14 years of Return on Capital Employed data on file, last reported at 39.75% in Q1 2026.

• On a quarterly basis, Return on Capital Employed rose 21129.0% year-over-year to 39.75% in Q1 2026; TTM through Mar 2026 was 39.75%, a 21129.0% increase from a year earlier, with the FY2025 full-year figure at 93.1%, up 4354.0% from the prior year.
• Return on Capital Employed for Q1 2026 stood at 39.75%, up from 123.1% in the prior quarter.
• Over the last five years, Return on Capital Employed for RLMD reached as high as 39.75% in Q1 2026 and fell as low as 451.66% in Q3 2025.
• Historically, Return on Capital Employed has averaged 155.65% across 5 years, with a median of 113.76% in 2023.
• Across the five-year window, Return on Capital Employed slumped 28591 bps in 2025 and soared 21129 bps in 2026, its largest moves.
• Year by year, Return on Capital Employed stood at 102.35% in 2022, then declined by 11 bps to 113.76% in 2023, then plunged by 82 bps to 207.24% in 2024, then surged by 41 bps to 123.1% in 2025, then surged by 68 bps to 39.75% in 2026.
• Per Business Quant data, the three most recent Return on Capital Employed figures were 39.75% in Q1 2026, 123.1% in Q4 2025, and 451.66% in Q3 2025.